5 Best Diversified Bank Stocks For 2014

Last week, GE Capital Corporate Finance announced it would be serving as an administrative agent for JAKKS Pacific Inc. (JAKK), which will be receiving a $75 million senior secured credit facility. The financial help, directed towards corporate purposes and capital expenditures should be of great help to the toy designer and manufacturer, since 2013 was a rough year on earnings, and cash flow hit a historical low point with losses of over $32 million. However, the company seems confident it can turn results around and following management�� optimistic claim about 2014, several investment gurus like Paul Tudor Jones (Trades, Portfolio) and Jim Simons (Trades, Portfolio) hedge fund have bought JAKKS stock. So, let�� see what this toy designer has in store for the future.

Will 2013�� Challenges Be This year�� upside?

JAKKS hasn�� had the best of luck when it comes to product launches and financial earnings in the past, and the current anaemic economic situation has put yet another strain on consumer spending in the U.S. and Europe. But 2014 might be the growth year this toy manufacturer has been waiting for. After 2012�� row of acquisitions, including Maui Inc. (July 2012), JKID Ltd. (September 2012), a joint venture with NantWorks LLC to develop technologically orientated toys, and a 50% joint venture with the Japanese animation production firm, Pacific Animation Partners, has helped the firm gain significant brand strength, which should help boost top and bottom line growth. The most recent expansion of the Daniel Tiger�� Neighborhood franchise, which has been very successful since its holiday season launch and will now be available at Target Corp. (TGT), Kmart and Barnes & Noble Inc. (BKS), should also contribute to sales growth.

10 Best Dividend Stocks To Own Right Now: Goldcorp Incorporated(GG)

Goldcorp Inc. engages in the acquisition, exploration, development, and operation of precious metal properties in Canada, the United States, Mexico, and Central and South America. It produces and sells gold, silver, copper, lead, and zinc. The company was founded in 1954 and is headquartered in Vancouver, Canada.

Advisors' Opinion:

• [By Jim Jubak]

  Gold reserves fell by 8%. That is a relatively small reduction, in comparison to those being declared by other gold miners recently—Goldcorp (GG), for example, declared a 15% reduction in reserves. Yamana Gold has been relatively aggressive in cutting the price assumptions it uses in calculating reserves (at $950 an ounce versus $1,300 an ounce at Goldcorp), so the low price of gold in 2013 has relatively less effect on Yamana's reserve calculations.

5 Best Diversified Bank Stocks For 2014: Opus International Consultants Ltd (OIC)

Opus International Consultants Limited is a supplier of multidisciplinary consultancy and project management services across a range of disciplines including, civil, mechanical and electrical engineering, and planning, environmental, architectural and property management. The Company operates in four segments: New Zealand, United Kingdom, Australia and Canada. Services supplied support asset development and asset management activities of the Company�� clients. Asset management services include property management and asset maintenance services predominantly using our engineering and environmental specialists. Asset development services include civil, mechanical and electrical engineering, planning, environmental and architectural work. Effective September 3, 2013, Opus International Consultants Ltda majority-owned unit of Opus Group Bhd acquired Stewart, Weir & Co Ltd. Advisors' Opinion:

• [By John McCamant]

  Nektar Therapeutics (NKTR) is expected to get FDA approval this year for its lead drug naloxegol, a once-a-day pill for opioid-induced constipation (OIC). The drug is licensed to AstraZeneca. NKTR will receive up to $245 million in milestone payments, plus royalties.

5 Best Diversified Bank Stocks For 2014: BIND Therapeutics Inc (BIND)

BIND Therapeutics, Inc., incorporated on May 19, 2006, is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC).

Accurins represent the evolution of targeted therapies and nanomedicine. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. The four components include Targeting ligands, Stealth and protective layer, Controlled-release polymer matrix and Therapeutic payload. The Company focuses to use its medicinal nanoengineering platform to develop Accurins in several therapeutic areas, with an initial focus on the treatment of various types of cancer. In addition, the Company entered into collaboration agreements with several biopharmaceutical companies to develop and commercialize Accurins that are based on its collaborators��therapeutic payloads. The Company�� programs include BIND-014, solid tumor accurin and hematologic cancer accurin.

Advisors' Opinion:

• [By Anna Prior]

  Bind Therapeutics sa(BIND)id a collaboration with Amgen Inc.(AMGN) has been ended after both companies agreed not to pursue an option to jointly develop a molecularly targeted cancer therapy. Bind Therapeutics shares fell 11% to $11.50 premarket.

• [By John Udovich]

  The biotech sector has been pretty exciting this year�with small cap biotech stocks Prana Biotechnology Limited (NASDAQ: PRAN) and TNI BioTech (OTCMKTS: TNIB) having recently produced noteworthy news for investors�while Acceleron Pharma, Inc (NASDAQ: XLRN), Ophthotech (NASDAQ: OPHT) and BIND Therapeutics (NASDAQ: BIND) have just�set term sheets for their upcoming IPOs. Just consider all of the following recent news:

• [By Garrett Cook]

  BIND Therapeutics (NASDAQ: BIND) was down, falling 10.56 percent to $11.52 after the company reported the closing of collaboration deal with Amgen (NASDAQ: AMGN).

5 Best Diversified Bank Stocks For 2014: A-Cap Resources Ltd (ACB)

A-Cap Resources Limited is an Australia-based mineral exploration company. The Company�� principal activity during the fiscal year ended June 30, 2012 (fiscal 2012), is exploration of its tenement portfolio in Botswana and the ongoing feasibility studies into the Letlhakane Uranium Project. The Company focuses on investment in Botswana in Southern Africa, where it holds over 5000 square kilometer of exploration licenses. The Company�� projects include Botswana project, Letlhakane project, Mea-Coal project, Bolau-Coal project and Southern Pans project. The Company�� 100% owned Letlhakane Uranium Project is located in northeast Botswana. In July 2012, A-Cap announced the discovery of two new coal projects in Botswana, transforming the Company into a multi-commodity exploration outfit. Advisors' Opinion:

• [By John Heinzl]

  You'll notice that these numbers don't add up to $1.4988. That's because the 2012 distribution also contained a hefty chunk of return of capital (70.489 cents). ROC isn't taxable immediately; rather, it is subtracted from the adjusted cost base (ACB) of the units, which gives rise to a larger capital gain, or smaller capital loss, when the units are ultimately sold. Many REITs and mutual funds also distribute ROC. ROC can be a bit of a headache for investors. If you hold BIP in a non-registered account, you (or your accountant), will need to track those ROC payments in order to keep your ACB up to date. Knowing the ACB is necessary to calculate your capital gain, or loss, when it comes time to sell.